A
Y~MB~R of studies have identified opiate receptors in several central nervous system areas concerned with transmission and processing of pain. 13' 24' 26' 27' 38' 39A4' 45 ' 54 The question now arises as to whether parenteral and intrathecal opiates work on these sites to achieve analgesia. The experimental evidence that morphine reduces the ascending nociceptive information by exerting a direct effect in the substantia gelatinosa 2"9" 24"25"3147' 53"55 led clinical workers to assess the analgesic effectiveness of low-dose spinal opiates administered either epidurally or into the cerebrospinal fluid (CSF) circulation. 1"3-5"1~176176 Powerful and prolonged analgesia is obtained with much lower doses of morphine than are required to control pain if the drug is given intravenously. Feasibility of intraventricular morphine-induced analgesia is supported by laboratory experiments showing that microinjection of this agent into the central gray matter produces long-lasting naloxone-sensitive analgesia, which is thought to be mediated by activation of local interneurons, resulting in increasing activity of the descending spinopetal inhibitory pathways, v' 8' 1H4,_~3,51, 54 We have found, when producing chronic spinal opiate analgesia in our clinic, that low-dose morphine injected into the cisterna magna may suppress pain in any anatomical location without producing concomitant respiratory depression. This observation persuaded us to initiate chronic intraventricular morphine in patients with intractable pain caused by orofacial and disseminated cancer. We have also administered intraventricular morphine therapy to patients with malignancies elsewhere.
Clinical Material and Methods
The nature and location of cancer, the distribution, duration, and rhythm of pain, and the previous therapies employed in our 17 patients before resorting to intraventricular morphine are reflected in Table 1 . Parenteral analgesics, including opiates, resulted in unsatisfactory control of pain in all cases. Hypophysectomy, bilateral cordotomy, and dorsal column stimulation produced transient and incomplete pain relief in four patients. Eleven of 14 patients treated with epidural morphine administration via externalized catheters achieved good ,to excellent analgesia for periods ranging from 1 to 6 months ( Table 1) . Seven of the responders developed tolerance to morphine, but in most cases failure of spinal analgesia was due to technical problems such as displacement of the catheters and epidural scarring or infection.
Prior to implanting the Ommaya reservoir, patients giving informed consent for intraventricular therapy received a morphine bolus into the cisterna magna (11 cases: 0.5 to 0.75 mg total dose) or the lumbar theca (three cases: 0.5 to 1 mg total dose) to assess the analgesic effect and the possible risks of subarachnoid morphine (Table 2) . Pain relief ranging from good to excellent and lasting for 6 to 48 hours was recorded in all cases without serious accompanying side effects ( Table 2 ). The reservoirs were inserted under local anesthesia, with the catheter tip in the frontal horn of the right lateral ventricle at the level of the foramen of Monro. On the day of surgery, and with the patient under intensive care, 0.2 to 1 mg of preservative-free sterile morphine chloride dissolved in saline solution (0.5 to 1 cc total volume) was given through the reservoir. The onset, quality, and duration of analgesia were noted, and vital signs, respiratory and cardiovascular parameters, and neurological function were evaluated repeatedly. The person responsible for home treatment was taught the technique of aseptic injection, which consists in Betadine skin preparation followed by reservoir tapping by means of a tuberculin syringe with a No. 25 needle. To prevent fibrosis of the skin over the reservoir, we recommended moving the site of injection from day to day. It has been our policy to reduce to a minimum the amount of oral and parenteral narcotics given prior to initiating intraventricular therapy, and then to discontinue these agents. Because of previous depression, insomnia, and anxiety, many patients were given amitriptyline and levomepromazine during the ventricular trial. Patients' relatives were given simple charts to record morphine doses delivered at home, and patients were reviewed periodically during the period of treatment.
Pain relief was conventionally graded as excellent (80% to 100% reduction), good (40% to 80%), fair (20% to 40%), and poor (less than 20%).
Results
The initial and final morphine dose, the duration of treatment, the onset and quality of analgesia, the physical changes, and the side effects observed in this series are summarized in Table 2 .
Pain Relief and Development of Tolerance
Since most patients were elderly, we used low morphine doses initially. Good to excellent analgesia lasting for 12 to 52 hours was achieved with morphine doses ranging from 0.25 to 1 mg. The onset of analgesia occurred within 2 to 30 minutes of drug instillation. Apart from pain relief, most patients reported decreased anxiety and a feeling of overall well-being derived from the absence of chronic pain, Duration of treatment ranged from 2 weeks to 4 months at the time of manuscript submission, at which time seven patients were still alive.
Some degree of tolerance to morphine occurred in 11 patients with the passage of time. Tolerance was more marked and appeared more rapidly in the three patients who received large amounts of parenteral opiates before initiating intraventricular treatment (Cases 6, 7, and 15). During the last week of his life, one patient (Case 6) received 16 mg of morphine to maintain an adequate level of analgesia. Six patients did not develop tolerance after treatment periods ranging from 1 to 31 months.
Physical Changes
Seven patients were noted to present miosis soon after morphine administration, but obvious changes in temperature, blood pressure, and heart or respiratory rates were not recorded. Sensory performance and motor power were unaltered in all cases. One patient had spontaneous nystagmic jerks after receiving the first morphine dose.
Side EfJ~Ts
Immediately after initiation of therapy, three patients complained of facial or generalized pruritus, and another developed urinary retention lasting for 2 to 3 days. Three patients were disoriented as to space and time during the first 2 days of treatment, and two of them also exhibited confusion and complex visual hallucinations during this period. These changes, like transient somnolence which occurred in four more patients, subsided spontaneously without discontinuation of therapy.
After receiving morphine for 1 month (1 mg daily dose) without presenting noticeable side effects, one patient with breast cancer (Case 13) developed temporal and spatial disorientation. Computerized tomography scan excluded intracranial pathology that would account for the neurological change. It is interesting that discontinuation of morphine did not result in recurrence of pain, nor in mental improvement. A similar intriguing "permanent" analgesia occurred in Case 11. This man enjoyed complete pain relief until therapy had to be discontinued because he developed an aseptic CSF reaction that could be controlled without removing the reservoir. Surprisingly, pain relief persisted and the patient remains free of pain 2 months after cessation of therapy.
One patient (Case 10) developed respiratory depression 4 hours after the first ventricular injection (1 rag); he had not been exposed to subarachnoid morphine prior to implantation of the reservoir. Naloxone (0.4 mg in an intravenous bolus, followed by continuous infusion of 2 mg during 19 hours) restored respiratory function without reversing analgesia. Subsequent very low doses of morphine (0.25 to 0.5 mg/24 hours) achieved excellent analgesia without causing respiratory depression.
One patient (Case 16) developed infection of the implanted reservoir with headache, fever, and meningeal signs; CSF culture was negative, and the symptoms disappeared 5 days after the reservoir was removed. The patient refused a second implantation and we performed stereotaxic mesencephalotomy. Two lesions, 4 and 8 mm from the midline and 5 mm posterior and inferior to the posterior commissure, were made with a Radionics electrode. Unequivocal analgesia involving the right side was accompanied by complete pain relief. Despite definite pinprick analgesia, pain recurred 6 weeks after the operation, together with a local burning sensation. A second trial of ventricular morphine resuited in almost complete control of pain (Table 2) .
Discussion
We have shown that intractable pain in terminal cancer patients is relieved by injecting small doses of morphine into the lateral cerebral ventricle. Analgesia, which appears within a few minutes of injection irrespective of the anatomical location of pain, together with a favorable behavioral response, can be maintained for several months without resorting to additional medical or surgical therapies. The side effects of treatment are short-lasting, and the most dreaded sequela (respiratory depression ~5' 22) occurred in only one instance and was easily reversed by naloxone therapy. The fact that this agent did not reverse analgesia in our patient supports the suggestion that opiate analgesia is mediated by a subpopulation of receptors that are probably located on neurons different from those regulating respiratory depression. 2~176 It has been found that opiate iontophoresis excites some central gray matter neurons and inhibits others, but only inhibition is reversible by naloxone. 14 Naloxone has also failed in reversing intraventricular morphine-induced analgesia in the laboratory, 52 and stimulation-induced analgesia in man, 34"35 and it should be borne in mind that opiates may achieve pain relief by activating non-opiate analgesic systems. 32, 33 It is doubtful that persistent disorientation occurring in our patient (Case 13), who also developed "permanent" analgesia, can be attributed to morphine therapy. Disorientation as an isolated symptom does not occur with chronic morphine administered by other routes, 22 and the lack of improvement after cessation of treatment argues against a pharmacological origin. However, much caution is necessary because the possibility that ventricular morphine may result in lasting neurological changes does exist. Temporal and spatial disorientation linked to complete pain relief lasting for a month has also been observed after short-term intraventricular morphine in a woman with breast cancer (F San Emeterio, et al., personal communication, 1982). The fact that analgesia outlasted morphine administration is difficult to explain but, taking into account the complex and widespread influence of opiates upon hypothalamic function and pituitary hormones, 2-~ an unclear mechanism akin to that following hypophysectomy 16' 32' 36 might have been involved in the above-mentioned cases and in another patient (our Case l l) who also had a hormone-dependent cancer and developed "permanent" analgesia without accompanying neurological changes. Development of tolerance was not a serious problem in the present series, presumably because of the small doses of morphine employed. A low-level receptor activation may explain why repeated morphine microdoses did not result in the rapid and marked tolerance seen with high-dose oral or parenteral opiates. 37 Since cross-tolerance seems to occur between systemic and intraventricular morphine, it is advisable to reduce or discontinue parenteral administration prior to initiating ventricular therapy.
The interaction of exogenously given opiates and the endogenous transmitter modulator system is poorly understood at the present time, Extensive laboratory work suggests that opiates may directly inactivate some neural components throughout the ascending pain transmission pathways, or may result in activation of the endogenous centrifugal inhibitory system, or both.2.7-~.lt-14,24.31.33.47,51,53-55 Most probably, intraventricularly administered morphine acts at a supraspinal level, and the short latency of the analgesia observed in our patients, irrespective of the cranial or distal location of pain, is consistent with this hypothesis. It seems logical that for intraventricular morphine to elicit the complex anti-nociceptive behavioral response observed in our patients in such a short time, rapid diffusion of the drug from the ventricular lumen to the neurons to be acted upon is required, and the location of the central gray matter along the ventricular lumen favors this possibility.6'~3s4
We did not measure cisternal or lumbar morphine levels but, taking into account the low biotransformation rate into the CSF circulation, '829 it is possible that diffusion of the drug to more caudal levels in a concentration high enough to result in a direct spinal action could occur in such a manner that the analgesia elicited at the brain level is continued or reinforced by spinal analgesia. The fact that the rapid-onset analgesia we observed is exerted supraspinally is also supported by the fact that pain relief achieved in patients with pelvic malignancies occurred more rapidly following intraventricular injection than when morphine had been given into the lumbar theca. Furthermore, the mental changes produced by ventricular morphine were never seen after analgesic-effective cisternal injections, suggesting that they result from opiate interaction at supramedullary level. Provided this is true, it does not mean that intraventricular-elicited analgesia is necessarily operating at the same sites. A recent study 28 suggests that intraventricularly injected morphine achieves analgesia at a spinal level, and we observed that morphine injected into the cisterna magna failed to alleviate pain in one of our patients with a cervical spine sarcoma causing complete subarachnoid block. Thus, it may be necessary for the drug to gain the dorsal horn of the medullary segment involved in pain processing for analgesia to result. Experimental studies using radiolabeled opiates are necessary to determine the diffusion patterns of these agents into the CSF circulation.
According to the present results and those obtained by Leavens, et al. . 3~ Roquefeuil, et al., 43 and San Emeterio, et al. (personal communication, 1982) , chronic intraventricular morphine is a feasible and effective method of pain therapy. Like stimulation-induced analgesia, 2~' 35~42 intraventricular morphine achieves pain relief without interfering with other sensory modalities, and in our hands it has been more effective than the former technique for the management of diffuse and bilateral pain caused by orofacial, neck, and disseminated cancer which so frequently evades neurosurgical ablative procedures. The surgical risk of reservoir implantation is low and the hazard of infection and the short-lasting pharmacological side effects occasionally seen at initiation of therapy are counterweighed by the potential dangers and the neurological deficits linked to major ablative procedures, Our experience with ventricular morphine is preliminary, and subsequent controlled trials are needed to evaluate this form of therapy and determine its place in the management of chronic pain. The occurrence of unpredictable mental changes, even in a small proportion of patients, would entail a serious limitation. By contrast, development of tolerance is not an obstacle, and the availability of new drugs liable to retain the analgesic effects while eliminating the unwanted ones by activating specific receptor populations, 2~176 administered in continuous or alternating regimes by means of implantable devices, 3"17' j9"37 will probably circumvent tolerance and decrease the risk of infection linked to multiple injections.
